Category: Uncategorized

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joins Steve Darling from Proactive Vancouver to provide an update that a protocol is planned for a physician initiated phase 2 clinical study of NP-120 for COVID-19 infected patients in South Korea. Moreau telling Proactive how they are fast-tracked for this trial and what the next steps will be. Click the image above to see interview …

Today we have the CEO of Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF) Mr. Christopher Moreau sitting down with us for an exclusive interview regarding the company’s operations surrounding Covid-19.EI) Mr. Moreau, for investors that are not very familiar with Algernon Pharmaceuticals, could you tell us the vision of Algernon and how it all began?   click below to view the articles Equity Insight – Interview with CEO of Algernon Pharmaceuticals Equity Insight –  2 Coronavirus Stocks On Watch: Part 2 …

by Ben Adams Jan 29, 2020 Algernon Pharmaceuticals has chosen contract research organization Novotech to help run its phase 2 idiopathic pulmonary fibrosis and chronic cough trial for its experimental med NP-120 (Ifenprodil). The study is slated to start in the next quarter, and Algernon will tap Novotech’s experience across the Asia-Pacific region. In addition, the CRO has penned a letter of intent to make an equity investment in Algernon worth around CA$220,000. …

by Joana Carvalho on August 2nd, 2019 Algernon, a pharmaceutical company focused on repurposing generic medications that are not available in the U.S. or EU, is investigating if NP-120 might treat IPF due to its potent anti-fibrotic properties. Of note, drug repurposing refers to the process of testing a medication with established safety in conditions other than those for which it was originally intended. NP-120 belongs to a class of drugs known as N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonists. Algernon is currently investigating how its mechanism of action may benefit people with IPF. The company recently announced preclinical study results …

by Kate Wilson on August 1st, 2019 Today, Algernon announced that Bemethyl (NP-135) and Bromantane (NP-160)—both drugs developed by the Soviet Union to boost the performance of its military and Olympic athletes—are effective for treating chronic kidney disease (CKD), and non-alcoholic steatohepatitis (NASH): inflammation caused by a buildup of fat in the liver. The company confirmed in multiple animal studies that the two substances were able to reduce fibrosis—a kind of scarring caused by a buildup of connective tissue—at highly statistically significant rates. A press release suggests that the drugs outperformed known anti-fibrotic agents named Telmisartan and Cenicriviroc. “We are …

Since donning its new corporate identity earlier this year, Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) has been busy advancing its research and its business. Much like the classic novel the clinical stage Company derived its name from, which built its theme around change, Algernon is shifting to become a phase II clinical trial Company. Having changed its name to Algernon in February 2019, the corporate shift was intended to align its operation with its main strategy to be a global leader in the treatment of liver disease, non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). NASH is a common liver …